{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "mesenchymal Wharton Jelly Mesenchymal stem cells",
            "NStudiesAvail": 430269,
            "NStudiesFound": 40,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 40,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose I"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02945449"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.\n\nNumber of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03288571"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03751735"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03299413"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.\n\nWJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: WJ-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04313322"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [
                              "ALSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells isolated from Wharton's jelly"
                        ],
                        "ArmGroupLabel": [
                              "Treatment arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04651855"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)",
                              "Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo",
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-UMC-BETA/placebo",
                              "Placebo/XCEL-UMC-BETA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03003364"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02963727"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.\n\nCohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCTC-0010 Dose Escalation"
                        ],
                        "ArmGroupLabel": [
                              "MSCTC-0010 Dose Escalation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03158896"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [
                              "MSC-COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.\n\nday 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg",
                              "Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC Arm",
                              "Placebo Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [
                              "PREVENT-TAHA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.",
                              "In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)",
                              "Other: Conventional Treatment",
                              "Other: Conventional Treatment"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2 (Control Group)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [
                              "WJ-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "RP patients with progressive visual acuity and visual field loss: before stem cell application.",
                              "RP patients, after stem cell applications."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton's jelly derived mesenchymal stem cell",
                              "Biological: Wharton's jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Before application",
                              "After application"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04224207"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.",
                              "Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Wharton's jelly derived Mesenchymal stem cells.",
                              "Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single subtenon injection of Wharton jelly-derived mesenchymal stem cells will be performed on a single eye after randomization",
                              "Single subtenon injection of mesenchymal stem cell exosomes (Wharton jelly-derived)will be performed on a single eye after randomization.",
                              "A single subtenon injection of saline will be performed on a single eye after randomization."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cells",
                              "Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Wharton jelly-derived mesenchymal stem cell",
                              "Mesenchymal stem cell exosome (Wharton jelly-derived)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05413148"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [
                              "WJ-MSC-AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton's jelly- Derived Mesenchymal Stem Cells Transfer"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: intracoronary human umbilical WJ-MSC transfer"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03866330"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [
                              "WANICHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nAssigned Interventions:\n\nBiological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo",
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nBiological/Vaccine:\n\nWJMSCs Vs.placebo",
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nBiological/Vaccine:\n\nWJMSCs Vs.placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS",
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS",
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS"
                        ],
                        "ArmGroupLabel": [
                              "Placebo Infusion PBS",
                              "Single dose Infusion WJMSCs",
                              "Infusion WJMSCs multiple doses"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [
                              "PERISCOPE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.\n\nIn addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.\n\nPeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton\u00b4s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix .",
                              "The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton\u00b4s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.",
                              "Procedure: Surgery by sternotomy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03798353"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [
                              "WJ-ICMP Tria"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure",
                              "Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: WJMSCs Vs. placebo",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Intracoronary infusion WJMSCs",
                              "Intravenous infusion WJMSCs"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.",
                              "Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: HAM and HUMCWJ Injections"
                        ],
                        "ArmGroupLabel": [
                              "HAM and HUMCWJ Injections (Group 1)",
                              "Control (Group 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [
                              "UwmWjmscAls"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Biological: Cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic WJ-MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02881476"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords"
                        ],
                        "ArmGroupLabel": [
                              "COVID-19 patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [
                              "scorem-cells"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.",
                              "Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton's jelly-derived mesenchymal cells",
                              "Biological: Wharton's jelly-derived mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Comparison/control group",
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 \u00b5g teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.",
                              "subcutaneous injection of 20 \u00b5g teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: WJ-MSC",
                              "Drug: Teriparatide",
                              "Drug: Teriparatide"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC group",
                              "Teriparatide group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018637"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [
                              "Magnovision"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.",
                              "rEMS applications were repeated 10 times with a 1-week interval.",
                              "WJ-MSC was applied only one time for both eyes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton jelly derived mesenchymal stem cell",
                              "Device: Repetitive electromagnetic stimulation",
                              "Device: Repetitive electromagnetic stimulation",
                              "Biological: Wharton jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC combine witf rEMS",
                              "Only rEMS",
                              "Only WJ-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04877067"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.",
                              "Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Cardiac Drug",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Active Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03404063"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).",
                              "Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).",
                              "Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC",
                              "Biological: UC-MSC",
                              "Biological: UC-MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC group 1",
                              "MSC group 2",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03529136"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [
                              "COVIDMES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton-Jelly mesenchymal stromal cells on D1 and D3",
                              "Placebo on D1 and D3"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment A",
                              "Treatment B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05093725"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [
                              "WAIAMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Standard therapy+Intravenous infusion PBS in patients with AMI",
                              "Standard therapy+Intravenous infusion WJMSCs in patients with AMI"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous infusion placebo",
                              "Biological: Intravenous infusion WJMSCs",
                              "Biological: Intravenous infusion placebo",
                              "Biological: Intravenous infusion WJMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Placebo PBS",
                              "WJMScs"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04551443"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In this group, the subjects will use Conditioned Medium topical therapy for 2 weeks The Conditioned Medium gel will be applied to the wound and closed by transparent dressing.\n\nThe evaluation and dressing replacement will be done every week for 2 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conditioned Media"
                        ],
                        "ArmGroupLabel": [
                              "Conditioned Medium Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04134676"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).",
                              "CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Triamcinolone acetonide",
                              "Biological: CELLISTEM-OA"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 (control-Triamcinolone acetonide)",
                              "Group 2 (experimental- CELLISTEM-OA)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04863183"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Umbilical cord"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01166776"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [
                              "STROMA-CoV2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord Wharton's jelly-derived human",
                              "Other: NaCl 0.9%"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "NaCl"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.",
                              "This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up",
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up"
                        ],
                        "ArmGroupLabel": [
                              "patients with complete transection of the spinal cord",
                              "patients with SCI without total transaction."
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04288934"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.",
                              "Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Control group",
                              "Preeclampsia group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03562715"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.",
                              "50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Chondrogen",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Active Participant of Phase 2B Clinical Study Chondrogen",
                              "Placebo Participant of Phase 2B Clinical Study Chondrogen"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520945"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients randomized to the active treatment group: Transcoronary or trans-bypass graft administration of CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin) will be performed using a dedicated cell delivery catheter.\n\nThe cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties.",
                              "Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: CardioCell",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Active Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03418233"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).",
                              "Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: CardioCell",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Active Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03423732"
                        ]
                  }
            ]
      }
}